China's Zhongmou seeks to create a ‘one-size-fits-all’ rival to Luxturna

An under-the-radar Wuhan-based biotech startup says that its gene therapy for an inherited form of vision loss has generated early but promising results in a handful of patients. The startup, Zhongmou Therapeutics, has attracted little ...